EU-MALARIA-FUND
19.6.2020 09:39:05 CEST | Business Wire | Press release
The EU Malaria Fund (EUMF) yesterday presented its first investment into Achilles Vaccines srl at the premises of Fondazione Monte dei Paschi di Siena in Italy. The investment supports development of a novel Malaria vaccine on its versatile technology platform transforming bacteria, natural carriers of molecules harmful to human health, into an efficient delivery system of bio antigenic molecules to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. The EUMF funding, with support from Fondazione TLS, will also be used to advance Achilles’ project to develop a novel human monoclonal antibody against COVID-19.
The first recipient of EUMF funding, Achilles, is a Siena-based biotech company specialising in research on malaria, antimicrobial resistance and, lately, COVID-19. “Achilles Vaccines is proud to contribute to the search for vaccines to eliminate malaria, a disease that faded into the background in these dramatic months, but which still claims significantly more victims than COVID-19 does, especially among children. Thanks to the guidance of Dr Rappuoli, we escape the challenge of finding a therapeutic and prophylactic drug with our monoclonal antibody, that finally makes the pandemic in which we find ourselves manageable”, said Riccardo Baccheschi, President and CEO of Achilles.
Holm Keller, Managing Director of EUMF and Chairman of kENUP Foundation said: “The EU Malaria Fund has high hopes, that the investment at the heart of the Siena vaccine hub in Italy will help to accelerate the eradication of Malaria. I am delighted that in these trying times, innovative Italian companies, like Achilles, will play a role in developing solutions against COVID-19".
The European Commission and the European Investment Bank (EIB) are investing €111 million into the fund. “Vaccines are important for disease prevention,” said Ambroise Fayolle, EIB Vice President in charge of innovation. “But often they also generate lower revenues than drugs and other health care services and are thus less attractive for private investors. This is why initiatives like the EU Malaria Fund are so important. We are glad to see the first investment of this Fund materialise so quickly and hope that it will allow AchilleS to progress in this important field of research.”
“We are very proud to be the first Italian foundation to invest in the EU Malaria Fund. With a 1 million euros amount, the Fondazione MPS is pursuing two main goals in a long-term vision: supporting scientific research for those diseases that have a big impact on public health and attracting financial resources with long-term benefits for the province of Siena. – said Carlo Rossi, Chairman of Fondazione Monte dei Paschi di Siena, “We also appreciate that the EU Malaria Fund will support the COVID-19 research, as it represents, at the moment, the most important worldwide sanitary challenge that requires huge common efforts”.
The EIB and WHO support the development of the EU Malaria Fund. “Together with WHO’s technical expertise we are confident of accelerating the development of new and innovative tools. The first investment of the EU Malaria Fund in Achilles will meaningfully advance the renewed efforts in our fight against Malaria” said Dr Pedro Alonso, Director of the World Health Organisation’s Global Malaria Programme.
The EUMF is a public-private partnership between the European Union, international organisations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. Further information can be found at www.controlMalaria.eu .
The video of the event can be found at https://www.controlmalaria.eu/news
View source version on businesswire.com: https://www.businesswire.com/news/home/20200619005083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International’s Alipay+ and The New York Liberty Celebrate Season of Sustainability Impact on Community, Environmental and Youth Empowerment16.11.2026 05:08:00 CET | Press release
The first-season partnership delivers tangible results: 219 trees planted, 650 pairs of shoes donated, and youth empowered through inaugural Math Hoops tournament Ant International’s Alipay+, a leading cross-border fintech services platform, and the WNBA’s New York Liberty, today announced the results of their joint sustainability initiatives for the season. Marking the first season of the multi-year collaboration, Alipay+ and the New York Liberty planted a total of 219 trees — one for every three-pointer made by the New York Liberty and Alipay+ in-game fan contestants during home games at Barclays Center this season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261115082353/en/ Students celebrate during the inaugural Liberty NBA Math Hoops Regional Tournament. In addition to the on-court tree-planting pledge, the partners concluded their fan-driven Sneaker Drive, collecting 650 pairs of shoes to support environmental cons
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
